PP_1170x120_10-25-21

Acceleron Pharma

Merck to acquire Acceleron Pharma

Merck to acquire Acceleron Pharma

KENILWORTH, N.J. — Merck and Acceleron Pharma announced on Thursday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. Acceleron is focused on harnessing the power of the transforming growth factor

Adheris Health